Novartis patent for oral form of top-selling MS drug obvious, IP Australia says

Christian Dimitriadis 2019-05-13 12:31 pm By Miklos Bolza | Sydney

Please login to bookmark

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au